Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
DYN

DYN - Dyne Therapeutics Inc Stock Price, Fair Value and News

33.07USD-0.62 (-1.84%)Market Closed

Market Summary

DYN
USD33.07-0.62
Market Closed
-1.84%

DYN Alerts

  • 4 major insider sales recently.

DYN Stock Price

View Fullscreen

DYN RSI Chart

DYN Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-11.23

Price/Sales (Trailing)

315.84

Price/Free Cashflow

-13.11

DYN Price/Sales (Trailing)

DYN Profitability

Return on Equity

-53.84%

Return on Assets

-49.28%

Free Cashflow Yield

-7.63%

DYN Fundamentals

DYN Revenue

Revenue (TTM)

9.1M

Rev. Growth (Yr)

101.07%

Rev. Growth (Qtr)

71.4%

DYN Earnings

Earnings (TTM)

-257.4M

Earnings Growth (Yr)

-48.57%

Earnings Growth (Qtr)

1.48%

Breaking Down DYN Revenue

Last 7 days

6.9%

Last 30 days

12.6%

Last 90 days

18.2%

Trailing 12 Months

173.3%

How does DYN drawdown profile look like?

DYN Financial Health

Current Ratio

21.83

DYN Investor Care

Shares Dilution (1Y)

49.86%

Diluted EPS (TTM)

-3.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.1M000
20234.2M5.9M7.2M7.6M
2022806.0K1.0M1.8M2.9M
2021190.0K376.0K560.0K742.0K
2020265.0K240.0K215.0K0
2019000290.0K
20180000

Tracking the Latest Insider Buys and Sells of Dyne Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 12, 2024
high susanna gatti
acquired
221,600
5.54
40,000
chief operating officer
Jun 12, 2024
high susanna gatti
sold
-1,334,200
33.355
-40,000
chief operating officer
Jun 11, 2024
mcneill jonathan
sold
-57,132
31.34
-1,823
chief business officer
Jun 11, 2024
scalzo richard william
sold
-41,713
31.34
-1,331
svp, head of finance & admin.
Jun 11, 2024
beskrovnaya oxana
sold
-66,942
31.34
-2,136
chief scientific officer
Jun 11, 2024
farwell wildon
sold
-82,427
31.27
-2,636
chief medical officer
Jun 11, 2024
high susanna gatti
sold
-164,582
31.23
-5,270
chief operating officer
Jun 10, 2024
scalzo richard william
sold
-48,065
30.23
-1,590
svp, head of finance & admin.
Jun 10, 2024
high susanna gatti
sold
-2,419,200
30.24
-80,000
chief operating officer
Jun 10, 2024
high susanna gatti
acquired
443,200
5.54
80,000
chief operating officer

1–10 of 50

Which funds bought or sold DYN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
added
50.00
1,184,000
1,710,000
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
119
348,117
442,117
0.06%
May 17, 2024
Ikarian Capital, LLC
sold off
-100
-3,802,470
-
-%
May 17, 2024
Artal Group S.A.
added
24.63
26,895,900
43,094,900
1.10%
May 17, 2024
Aspect Partners, LLC
unchanged
-
10,940
20,583
0.02%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
29.93
813,007
1,271,420
-%
May 16, 2024
COMERICA BANK
unchanged
-
2,640
4,968
-%
May 16, 2024
JANE STREET GROUP, LLC
added
373
2,238,950
2,484,780
-%
May 15, 2024
Sofinnova Investments, Inc.
added
91.08
41,501,900
54,981,500
3.06%
May 15, 2024
Voya Investment Management LLC
added
98.38
1,668,360
2,184,160
-%

1–10 of 42

Are Funds Buying or Selling DYN?

Are funds buying DYN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DYN
No. of Funds

Unveiling Dyne Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 04, 2024
ra capital management, l.p.
6.4%
5,213,661
SC 13G
Feb 14, 2024
deep track capital, lp
3.26%
2e+06
SC 13G/A
Feb 14, 2024
citadel advisors llc
5.0%
6
SC 13G/A
Feb 12, 2024
mpm bioventures 2018, l.p.
4.0%
3,216,844
SC 13G/A
Feb 09, 2024
atlas venture fund xi, l.p.
9.0%
7,326,117
SC 13G/A
Jan 29, 2024
blackrock inc.
6.2%
3,788,682
SC 13G
Jan 19, 2024
deep track capital, lp
5.55%
4,500,000
SC 13G
Jan 19, 2024
deep track capital, lp
3.26%
2e+06
SC 13G/A
Feb 14, 2023
deep track capital, lp
5.15%
2,684,200
SC 13G/A
Feb 14, 2023
logos global management lp
4.1%
2,150,000
SC 13G/A

Recent SEC filings of Dyne Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
4
Insider Trading
Jun 11, 2024
144
Notice of Insider Sale Intent
Jun 11, 2024
144
Notice of Insider Sale Intent
Jun 11, 2024
144
Notice of Insider Sale Intent
Jun 11, 2024
144
Notice of Insider Sale Intent
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading

Peers (Alternatives to Dyne Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Dyne Therapeutics Inc News

Latest updates
MarketBeat5 hours ago

Dyne Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q32020Q22020Q12019Q42019Q32018Q4
Revenue71.4%3,002,0001,751,5002,189,0002,207,0001,493,0001,342,500903,000441,000230,000182,000184,000210,000166,000--24,00067,000110,000-
Operating Expenses2.2%69,157,00067,688,50062,273,00066,736,00045,464,00040,145,00042,279,00052,755,00035,783,00051,960,00042,766,00030,165,00025,134,00013,520,0008,675,0007,853,000-3,629,000-
  S&GA Expenses178.4%24,618,0008,844,0007,022,0007,606,0007,928,0006,955,0007,609,0006,091,0007,547,0009,659,0006,256,0006,293,0006,509,0003,841,0001,341,0001,764,000-647,000-
  R&D Expenses-24.3%44,539,00058,844,50055,251,00059,130,00037,536,00033,190,00034,670,00046,664,00028,236,00042,301,00036,510,00023,872,00018,625,0009,679,0007,334,0006,089,000-2,982,000-
EBITDA Margin-----------1401221802001,637818---
EBT Margin------------960-832-1,233-1,372-11,208-5,604---
Net Income1.5%-65,649,000-66,638,000-60,210,000-64,902,000-44,187,000-38,827,000-41,385,000-52,304,000-35,583,000-51,786,000-42,582,000-29,955,000-24,968,000-13,920,000-8,982,000-7,886,000-5,403,500-5,871,000-
Net Income Margin8.9%-28.13-30.88-28.78-31.84-42.28-57.64-103-175-198-201-225-259-------
Free Cashflow-124.4%-78,728,000-35,088,000-50,769,000-55,892,000-47,138,000-29,711,000-43,691,000-31,170,000-52,140,000-30,058,000-27,833,000-46,888,000-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Assets216.4%522165205251289306300340388426467467492353381----
  Current Assets277.3%488129168213249266258298344382425461487349380--15.008.00
    Cash Equivalents123.7%272122130168181172145136148201229258311301380--15.008.00
  Net PPE-4.2%5.005.005.005.006.006.006.005.006.005.003.003.002.002.001.00--1.000.00
Liabilities-40.1%44.0074.0053.0045.0047.0054.0050.0053.0051.0057.0053.0015.0013.0011.0015.0011.006.002.004.00
  Current Liabilities-56.2%22.0051.0030.0020.0022.0028.0023.0026.0023.0029.0023.00--11.005.00--2.001.00
Shareholder's Equity423.7%47891.00152207242252250287336368414453478342367-8.0014.00-
  Retained Earnings-10.4%-698-632-565-505-440-396-357-316-264-228-176-134-104-79.18-50.53---19.75-4.89
  Additional Paid-In Capital62.5%1,176724718713683650608605601597591587582422417--6.000.00
Shares Outstanding41.7%87.0061.0061.0061.0058.0056.0052.0052.0052.0052.0051.0050.00-------
Float----504---216-------629---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Cashflow From Operations-124.4%-78,537-35,006-50,602-55,642-46,908-29,192-42,805-30,909-50,739-28,068-26,952-46,150-18,393-20,036-11,886-7,298-7,288---
  Share Based Compensation247.4%19,9065,7304,8764,7494,6173,8323,8273,0314,4886,0133,6384,2393,6524,2152,23575.0066.00---
Cashflow From Investing-786.5%-179,83726,19612,82117,23227,06219,23751,65818,443-2,136-235-2,848-6,434-128,375-45,223-156-71.00-211---
Cashflow From Financing277715.0%408,38814745424,90628,81537,20370.0099.0018.0089.0045725.00157,250-11,194379,976-11,908---
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

DYN Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 44,539$ 37,536
General and administrative24,6187,928
Total operating expenses69,15745,464
Loss from operations(69,157)(45,464)
Other income (expense):  
Interest income3,0021,493
Other income (expense), net506(216)
Total other income (expense), net$ 3,508$ 1,277
Net loss per share - basic$ (0.81)$ (0.78)
Net loss per share - diluted$ (0.81)$ (0.78)
Weighted average common shares outstanding, basic81,043,74156,325,864
Weighted average common shares outstanding, diluted81,043,74156,325,864
Comprehensive loss:  
Net Income (Loss)$ (65,649)$ (44,187)
Other comprehensive loss:  
Unrealized (losses) gains on marketable securities, net(132)368
Comprehensive loss$ (65,781)$ (43,819)

DYN Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 272,035$ 121,626
Marketable securities181,5121,474
Prepaid expenses and other current assets34,5946,275
Total current assets488,141129,375
Property and equipment, net4,5784,780
Right-of-use assets27,64028,612
Restricted cash1,9202,315
Total assets522,279165,082
Current liabilities:  
Accounts payable7,21422,936
Accrued expenses and other current liabilities10,39323,439
Lease liabilities4,7564,720
Total current liabilities22,36351,095
Lease liabilities, net of current portion21,86122,695
Total liabilities44,22473,790
Stockholders’ equity  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 202300
Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 87,089,649 and 61,468,743 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively96
Additional paid-in capital1,176,337723,796
Accumulated other comprehensive loss(132)0
Accumulated deficit(698,159)(632,510)
Total stockholders’ equity478,05591,292
Total liabilities and stockholders’ equity$ 522,279$ 165,082
DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEdyne-tx.com
 INDUSTRYBiotechnology
 EMPLOYEES134

Dyne Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Dyne Therapeutics Inc? What does DYN stand for in stocks?

DYN is the stock ticker symbol of Dyne Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dyne Therapeutics Inc (DYN)?

As of Fri Jun 14 2024, market cap of Dyne Therapeutics Inc is 2.89 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DYN stock?

You can check DYN's fair value in chart for subscribers.

What is the fair value of DYN stock?

You can check DYN's fair value in chart for subscribers. The fair value of Dyne Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Dyne Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DYN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Dyne Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether DYN is over valued or under valued. Whether Dyne Therapeutics Inc is cheap or expensive depends on the assumptions which impact Dyne Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DYN.

What is Dyne Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, DYN's PE ratio (Price to Earnings) is -11.23 and Price to Sales (PS) ratio is 315.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DYN PE ratio will change depending on the future growth rate expectations of investors.